Insmed(INSM)
Focus: Insmed is a public biotechnology company specializing in inhalable liposomal therapeutics across neurology, rare diseases, cardiovascular, respiratory, and ophthalmology. With 1-50 employees and $305M in FY2025 revenue, it operates as a lean, focused biotech with significant R&D investment.
Profile data last refreshed 9h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
0
About Insmed
AI assessmentNot HiringNo open roles listed right now. Follow Insmed to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$305M
Key Products
Declining
LOE Approaching
BLA-approved product approaching loss of exclusivity with no specified indication; likely mature revenue contributor at risk.
Help build intelligence for Insmed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.